InvestSMART

PharmAust Limited (ASX: PAA) - Announcements

Current share price for PAA : $0.230 0.015 (6.98%)+

ASX company news and announcements for PharmAust Limited (PAA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PharmAust Limited (PAA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PharmAust Limited (PAA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PharmAust Limited (PAA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- PharmAust Rights Issue Reaches Minimum Subscription 12 Mar 2019 10:53AM $0.035 $0.230 risen by 557.14%
- PharmAust Intellectual Property Update 5 Mar 2019 11:21AM $0.032 $0.230 risen by 618.75%
- Appendix 4D & Financial Report 1 Mar 2019 8:14AM $0.032 $0.230 risen by 618.75%
- Offer Document - Rights Issue 26 Feb 2019 10:04AM $0.032 $0.230 risen by 618.75%
- Phase I Dog Trial with New Monepantel Tablets Commences 20 Feb 2019 8:58AM $0.037 $0.230 risen by 521.62%
- Letter to Shareholders 19 Feb 2019 9:15AM $0.039 $0.230 risen by 489.74%
- Epichem Awarded One-Year Contract Extension from DNDi 18 Feb 2019 2:26PM $0.040 $0.230 risen by 475%
- Letter to Optionholders 18 Feb 2019 9:14AM $0.048 $0.230 risen by 379.17%
- Section 708AA Notice 18 Feb 2019 9:12AM $0.048 $0.230 risen by 379.17%
- Appendix 3B 18 Feb 2019 9:12AM $0.048 $0.230 risen by 379.17%
- Non-Renounceable Rights Offer 18 Feb 2019 9:12AM $0.048 $0.230 risen by 379.17%
- Appendix 3B - Amendment 14 Feb 2019 2:03PM $0.047 $0.230 risen by 389.36%
- PAA Completes Successful Taste Mask Testing of New Tablet 11 Feb 2019 9:33AM $0.046 $0.230 risen by 400%
- Section 708 Notice 7 Feb 2019 6:45PM $0.046 $0.230 risen by 400%
- Appendix 3B 7 Feb 2019 6:42PM $0.046 $0.230 risen by 400%
- PharmAust Signs Agreement for US Phase I Trials in Dogs 7 Feb 2019 9:38AM $0.044 $0.230 risen by 422.73%
- PharmAust Completes Scaled Manufacture of Monepantel Tablets 7 Feb 2019 9:32AM $0.044 $0.230 risen by 422.73%
- PharmAust Appendix 4C and Shareholders' Update 31 Jan 2019 4:36PM $0.042 $0.230 risen by 447.62%
- PharmAust and Elanco Execute Data Sharing Agreement 29 Jan 2019 8:55AM $0.041 $0.230 risen by 460.98%
- Optimisation of Monepantel Uptake 21 Jan 2019 8:44AM $0.041 $0.230 risen by 460.98%
- Monepantel Principal Metabolite Shows Anti-Cancer Activity 14 Jan 2019 9:18AM $0.039 $0.230 risen by 489.74%
- PharmAust Develops Method for MPL/Analogue Manufacture 3 Dec 2018 9:41AM $0.038 $0.230 risen by 505.26%
- GMP Tablet Manufacture Commences for Canine Clinical Trials 13 Nov 2018 8:28AM $0.041 $0.230 risen by 460.98%
- Results of Annual General Meeting 9 Nov 2018 2:57PM $0.041 $0.230 risen by 460.98%
- AGM Presentation 9 Nov 2018 8:27AM $0.041 $0.230 risen by 460.98%

426 - 450 of 796 results

Page 18 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.